Renaud Felten
Renaud is an Assistant Professor in the Clinical Investigation Center and the Department of Rheumatology of Strasbourg, France. His research interests include immunosuppressive drug and inflammatory rheumatic diseases, especially spondyloarthritis. Renaud is a member of the Newsletter Sub-Comimttee.
| Type, n° | Date, time | Session | Author | Title |
|---|---|---|---|---|
| Oral 0058 | Wednesday, 31.05.2023 17:15 – 17:25 | Clinical aspects and Treatment of axSpA: effects and predictors of effects | Kiltz, U (Germany) | PREDICTION OF LOW DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB IN REAL WORLD – DATA FROM THE GERMAN AQUILA STUDY |
| Post-hoc analysis of the AQUILA study, to predict Low Disease Activity in patients with Ankylosing Spondylitis treated with secukinumab through machine learning methods and to identify predictors and their influence using artificial intelligence. | ||||
| Oral 0059 | Wednesday, 31.05.2023 17:25 – 17:35 | Clinical aspects and Treatment of axSpA: effects and predictors of effects | Baraliakos, X (Germany) | EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY |
| First Head-To-Head trial in axial spondyloarthritis. The aim was to compare the effect of secukinumab versus adalimumab biosimilar (SDZ-ADL) on spinal radiographic progression at 2 years. | ||||
| Oral 0061 | Wednesday, 31.05.2023 17:45 – 17:55 | Clinical aspects and Treatment of axSpA: effects and predictors of effects | Poddubnyy, D (Germany) | DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS |
| Post-hoc analysis of the SELECT clinical trial program, to assess the development of extra-musculoskeletal manifestations (IBD, uveitis and psoriasis) among patients treated with UPA 15 mg or placebo. | ||||
| Poster 0024 | Thursday, 01.06.2023 12:00 – 12:25 | Poster Tour – Contemporary clinical topics in psoriatic arthritis | Ferrito, M (Italy) | RETENTION RATE OF TNF INHIBITORS (TNFI), ANTI-IL17, AND ANTI-IL12/23 DRUGS IN A SINGLE-CENTER COHORT OF PSORIATIC ARTHRITIS PATIENTS |
| Evaluation of the retention rate of bDMARDs with different mechanism of action (MoA) (TNFi vs non-TNFi) and factors associated with drug suspension in PsA patients from a retrospective cohort from a single-center (total of 241 bDMARDs therapy courses). | ||||
| Poster 1107 | Friday, 02.06.2023 09:30 – 10:30 | Poster View 4 | Magrey, M (USA) | BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES |
| Post-hoc analysis from the MOBILE-1 and 2 studies, to assess the efficacy of bimekizumab in TNFi-naïve or –insufficient responders patients with active nr-axSpA and r‑axSpA through Week 52 across multiple key endpoints. | ||||
| Poster 1543 | Saturday, 03.06.2022 10:30 – 11:30 | Poster View 6 | Ogdie, A (USA) | EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PSA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT |
| Post-hoc analysis from the KEEPsAKE 1 and 2 studies, to assess response rates in PsA patients with limited (5 to ≤ 8) and extensive (≥ 9) swollen joint count after risankizumab to examine its efficacy according to the extent of joint involvement. | ||||